Biogen to apply for approval for antidepressant in 2022

After a short dialog with the authorities and its partner, Sage, Biogen is planning to start the application process for marketing authorization for its depression drug zuranolone in 2022. This is despite the fact that a recent study did not generate overwhelmingly convincing results.


A press release from Biogen and Sage reports that applications for marketing authorization for zuranolone will start in 2022.

If everything goes according to plan, Biogen will apply for approval from the FDA for zuranolone as a treatment for depression in the second half of 2022, and for postpartum depression in 2023.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs